2010
DOI: 10.1038/nbt.1607
|View full text |Cite
|
Sign up to set email alerts
|

Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

6
301
2
1

Year Published

2011
2011
2021
2021

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 369 publications
(310 citation statements)
references
References 37 publications
6
301
2
1
Order By: Relevance
“…In xenograft models of human acute myeloid leukemia (AML), "normal" environmental structures are restored after these models are released from leukemic burden by chemotherapy [38,39]. Changes in BM environment may have resulted from anatomical "crowding out" of normal blood cells and mesenchymal cells.…”
Section: Dissemination Of Malignant Cells Alters Normal Bm Nichesmentioning
confidence: 99%
See 2 more Smart Citations
“…In xenograft models of human acute myeloid leukemia (AML), "normal" environmental structures are restored after these models are released from leukemic burden by chemotherapy [38,39]. Changes in BM environment may have resulted from anatomical "crowding out" of normal blood cells and mesenchymal cells.…”
Section: Dissemination Of Malignant Cells Alters Normal Bm Nichesmentioning
confidence: 99%
“…These blasts are tightly anchored by OPN in this niche and induced into a quiescent phase by other unknown factors in a local microenvironment [52]. Therefore, the induction of cell cycle entry facilitates cytotoxic agents to eliminate LSCs in mouse models [38,52] and may be translated to clinical treatments.…”
Section: Lscs Hide In Distinct Preferential Niches In Response To Thementioning
confidence: 99%
See 1 more Smart Citation
“…Those drugresistant cells are localized in the osteoblastic niche of the bone marrow (Ishikawa et al, 2007;Saito et al, 2010). They are quiescent and thus are not killed by antiproliferative chemotherapeutic regimens targeting cell cycle or DNA replication.…”
Section: Introductionmentioning
confidence: 99%
“…In cases of disease remission where elimination of cycling progenitors is achieved, relapses are frequent because of resistant LSCs and the prognosis is poor. The two main options proposed to eradicate LSCs aim at pushing LSCs out of their protective bone marrow niche (Jin et al, 2006;Saito et al, 2010) or killing them by targeting their specific signaling pathways (Guzman et al, 2005;Xu et al, 2005). However, a large number of primary cells from patients are refractive to these treatments, suggesting that new strategies are likely needed to eradicate LSCs.…”
Section: Introductionmentioning
confidence: 99%